Condition: Hodgkin Lymphoma, Adult · Sponsor: State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
The HL-Russia-1 is a non-randomized, open-label, multicenter, phase III, 3-arm study. The primary objective is to assess efficacy, safety and progression-free survival (PFS) of different approaches (earle favorable, early unfavorable and advanced stages) to first line chemotherapy for classical Hodgkin Lymphoma (HL).
This description comes directly from the study's public registry record.
Vladislav Sarzhevskiy, PhD · +7-910-436-00-40 · vladsar100@gmail.com
Nikita Mochkin, PhD · +7-910-456-87-06 · nickmed@yandex.ru
Always discuss trial participation with your own doctor first.
| Tata Memorial Hospital | Mumbai, Opd-81 Main Building, Dr. E Borges Road, Parel 400012, India | Recruiting |
| The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation | Moscow, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04638790